# Lq3 Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lq3-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Morrisville, US
- Website: www.lq3pharma.com
- Total disclosed funding: $10M
- Latest round: Series A (Sep 10, 2014)
- Investors on record: 2

## About

Lq3 Pharmaceuticals is focused on developing innovative therapeutics to address unmet medical needs. Their approach combines scientific expertise with cutting-edge research to enhance patient outcomes.Founded in 2013 and headquartered in Morrisville, US, Lq3 Pharmaceuticals specializes in creating targeted therapies. The company received USD 10 mn in Series A funding from Canaan Partners and Envisia Therapeutics on September 10, 2014, which supports its ongoing development initiatives. The company has completed a total of 1 deal to date.Lq3 Pharmaceuticals develops a range of pharmaceuticals aimed at treating specific medical conditions. Their offerings are driven by research and innovation, focusing on improving the efficacy of treatments and patient care.Lq3 Pharmaceuticals' revenue model includes collaborations and partnerships with other healthcare organizations, although specific financial details have not been disclosed.Lq3 Pharmaceuticals plans to utilize the recent Series A funding of USD 10 mn to expand its research and development efforts. This includes designing new therapeutics aimed at chronic diseases and targeting expansion into European and Asian markets by 2025.

## Funding rounds

- Series A, Sep 10, 2014, $10M — Canaan Partners, Envisia Therapeutics Inc.

## Investors

- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series A
- Envisia Therapeutics Inc. — Series A